Abstract Details

Title Factors Associated with Length of Hospitalization in Patients Admitted with Transient Ischemic Attack

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P03 - (-)

Poster/Presentation
Number 194

Objective

Background BACKGROUND: Approximately 70% of all patients presenting with TIA are admitted to hospital in United States. The duration and cost of hospitalization and associated factors are poorly understood.

Design/Methods DESIGN/METHODS: We determined the national estimates of length of stay, mortality, and charges incurred in patients admitted with TIA (Diagnosis related code 524) using Nationwide Inpatient Survey (NIS) data from 2002 to 2010. All the variables pertaining to hospitalization were compared in three groups based on length of hospital stay (<1 day, 2-6 days, and ?7 days).

Results RESULTS: A total of 949,558 patients were admitted with the diagnosis of TIA during the study period. The length of hospitalization was <1 day, 2-6 days, and ?7 days in 232732 (24.4%), 662909 (70) %), and 53917 (5.6%) patients respectively. The mean hospitalization charges (95% confidence interval) were $ 8,348 (8123-8572), $14,471(14030-14911), and $34,035 (32280-35790) for patients hospitalized for <1 day, 2-6 days, and ?7 days, respectively. The rates of atrial fibrillation (8.3%, 13.1%, and 22.6%, p<.0001), congestive heart failure (1.1%, 1.9%, and 3.7%, p<.0001), chronic lung disease (11.4%, 14.7%, and 20.0%, p<.0001), coagulopathy (0.8%, 1.3%, and 2.7%, p<.0001) and renal failure (3.1%, 5.1%, and 11.7%, p<.0001) were associated with length of hospitalization. The use of thrombolytics (0.03%, 0.09%, and 0.1%, p<.0001) for ischemic stroke was very low among the three strata defined by length of hospitalization.

Conclusions CONCLUSIONS: Approximately 75% of patients admitted with TIA stay in the hospital for 2 or more days with the most important determinants being pre-existing medical co-morbidities. Longer duration of hospital stay is associated with 2-5 folds greater hospitalization cost.

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
Haralabos Zacharatos, MD	Dr. Zacharatos has nothing to disclose.
Hamza I. Maqsood, MD (Dept of Neurology)	Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca.
	No disclosure on file

��ɫ��

��ɫ��